Faculty, Staff and Student Publications
Publication Date
4-8-2024
Journal
Cancer Cell
DOI
10.1016/j.ccell.2024.02.011
PMID
38458188
PMCID
PMC11003852
PubMedCentral® Posted Date
4-8-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. SMARCA4 is among the most recurrently mutated genes in human cancer, including ∼30% of germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression to drive lymphomagenesis. Furthermore, monoallelic Smarca4 deletion drove GC hyperplasia with centroblast polarization via significantly increased rates of centrocyte recycling to the dark zone. Mechanistically, Smarca4 loss reduced the activity of TFs that are activated in centrocytes to drive GC-exit, including SPI1 (PU.1), IRF family, and NF-κB. Loss of activity for these factors phenocopied aberrant BCL6 activity within murine centrocytes and human Burkitt lymphoma cells. SMARCA4 therefore facilitates chromatin accessibility for TFs that shape centrocyte trajectories, and loss of fine-control of these programs biases toward centroblast cell-fate, GC hyperplasia and lymphoma.
Keywords
Animals, Humans, Mice, Chromatin, DNA Helicases, Haploinsufficiency, Hyperplasia, Lymphoma, B-Cell, Nuclear Proteins, Transcription Factors
Published Open-Access
yes
Recommended Citation
Deng, Qing; Lakra, Priya; Gou, Panhong; et al., "SMARCA4 Is a Haploinsufficient B Cell Lymphoma Tumor Suppressor That Fine-Tunes Centrocyte Cell Fate Decisions" (2024). Faculty, Staff and Student Publications. 3243.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3243
Graphical Abstract
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons